S1. Rituximab for ANCA-associated vasculitis: The experience in the United States

Presse Medicale

Volumn 42, Issue 4 PART2, 2013, Pages 530-532

  Clain, Jeremy M ^a   Specks, Ulrich ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CD20 ANTIGEN; CYCLOPHOSPHAMIDE; GLUCOCORTICOID; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; RITUXIMAB;

ANCA ASSOCIATED VASCULITIS; CHURG STRAUSS SYNDROME; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; HUMAN; LETTER; MAINTENANCE THERAPY; MICROSCOPIC POLYANGIITIS; UNITED STATES; UNSPECIFIED SIDE EFFECT; WEGENER GRANULOMATOSIS;

EID: 84875605046     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lpm.2013.01.048     Document Type: Letter

References (25)

1. Leget G.A., Czuczman M.S. Use of rituximab, the new FDA-approved antibody. Curr Opin Oncol 1998, 10(6):548-551.
2. Fisher LM. Non-Hodgkin's lymphoma is treatable by a new drug. New York Times 27 Nov 1997; Sect. A28.
3. Gurcan H.M., Keskin D.B., Stern J.N., Nitzberg M.A., Shekhani H., Ahmed A.R. A review of the current use of rituximab in autoimmune diseases. Int Immunopharmacol 2009, 9(1):10-25.
4. Eisenberg R. Update on rituximab. Ann Rheum Dis 2005, 64(Suppl. 4):iv55-iv57.
5. Specks U., Fervenza F.C., McDonald T.J., Hogan M.C. Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy. Arthritis Rheum 2001, 44(12):2836-2840.
6. Jennette J.C., Falk R.J., Bacon P.A., Basu N., Cid M.C., Ferrario F., et al. 2012 revised international chapel hill consensus conference nomenclature of vasculitides. Arthritis Rheum 2013, 65(1):1-11.
7. Jennette J.C., Falk R.J. Small-vessel vasculitis. N Engl J Med 1997, 337(21):1512-1523.
8. Einfeld D.A., Brown J.P., Valentine M.A., Clark E.A., Ledbetter J.A. Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains. Embo J 1988, 7(3):711-717.
9. Grillo-Lopez A.J. Rituximab: an insider's historical perspective. Semin Oncol 2000, 27(6 Suppl. 12):9-16.
10. Anolik J.H., Barnard J., Cappione A., Pugh-Bernard A.E., Felgar R.E., Looney R.J., et al. Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis Rheum 2004, 50(11):3580-3590.
11. Keogh K.A., Wylam M.E., Stone J.H., Specks U. Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2005, 52(1):262-268.
12. Cupps T.R., Edgar L.C., Fauci A.S. Suppression of human B lymphocyte function by cyclophosphamide. J Immunol 1982, 128(6):2453-2457.
13. Stevenson H.C., Fauci A.S. Activation of human B lymphocytes. XII. Differential effects of in vitro cyclophosphamide on human lymphocyte subpopulations involved in B-cell activation. Immunology 1980, 39(3):391-397.
14. Popa E.R., Stegeman C.A., Bos N.A., Kallenberg C.G., Tervaert J.W. Differential B- and T-cell activation in Wegener's granulomatosis. J Allergy Clin Immunol 1999, 103(5 Pt 1):885-894.
15. Keogh K.A., Ytterberg S.R., Fervenza F.C., Carlson K.A., Schroeder D.R., Specks U. Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial. Am J Respir Crit Care Med 2006, 173(2):180-187.
16. Stone J.H., Merkel P.A., Spiera R., Seo P., Langford C.A., Hoffman G.S., et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010, 363(3):221-232.
17. Stone J.H., Merkel P.A., Seo P., Spiera R., Langford C.A., Hoffman G.S., et al. Extended follow-up of treatment with rituximab versus cyclophosphamide for remission-induction of ANCA-Associated vasculitis: which subsets are at greatest risk for flare?. Arthritis Rheum 2011, 63(10 Supplement):S946-S947.
18. Rhee E.P., Laliberte K.A., Niles J.L. Rituximab as maintenance therapy for anti-neutrophil cytoplasmic antibody-associated vasculitis. Clin J Am Soc Nephrol 2010, 5(8):1394-1400.
19. Cartin-Ceba R., Golbin J.M., Keogh K.A., Peikert T., Sanchez-Menendez M., Ytterberg S.R., et al. Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener's): ten-year experience at a single center. Arthritis Rheum 2012, 64(11):3770-3778.
20. Kaushik V.V., Reddy H.V., Bucknall R.C. Successful use of rituximab in a patient with recalcitrant Churg-Strauss syndrome. Ann Rheum Dis 2006, 65(8):1116-1117.
21. Koukoulaki M., Smith K.G., Jayne D.R. Rituximab in Churg-Strauss syndrome. Ann Rheum Dis 2006, 65(4):557-559.
22. Pepper R.J., Fabre M.A., Pavesio C., Gaskin G., Jones R.B., Jayne D., et al. Rituximab is effective in the treatment of refractory Churg-Strauss syndrome and is associated with diminished T-cell interleukin-5 production. Rheumatology (Oxford) 2008, 47(7):1104-1105.
23. Saech J., Owczarczyk K., Rosgen S., Petereit H., Hallek M., Rubbert-Roth A. Successful use of rituximab in a patient with Churg-Strauss syndrome and refractory central nervous system involvement. Ann Rheum Dis 2010, 69(6):1254-1255.
24. Donvik K.K., Omdal R. Churg-Strauss syndrome successfully treated with rituximab. Rheumatol Int 2011, 31(1):89-91.
25. Cartin-Ceba R., Keogh K.A., Specks U., Sethi S., Fervenza F.C. Rituximab for the treatment of Churg-Strauss syndrome with renal involvement. Nephrol Dial Transplant 2011, 26(9):2865-2871.